ClinicalTrials.gg
CompletedNCT04839380SCRATCH-ADUpdated Oct 31, 2023Results posted

The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis

A Phase 2 interventional study of ruxolitinib cream in Atopic Dermatitis, sponsored by Incyte Corporation. Completed at 2 sites in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-10-31.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
49
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing ruxolitinib in Dermatitis, Atopic — 2 open to participants now, 3 under way, 1 of them phase 3. ruxolitinib · Dermatitis, Atopic.

Enrollment
11th of 15
49 · median 77
Started
2021
with 3 others
Phase 2
3 of 15
none open now
Registered
6th of 15
by date
Lead sponsor
13 of 15
Incyte Corporation

Among the 15 studies testing ruxolitinib in Dermatitis, Atopic, this one is the 11th largest by enrollment, is one of 4 that started in 2021, is one of 3 in phase 2, and was the 6th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 15 studies testing ruxolitinib in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing ruxolitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the effect of ruxolitinib cream on itch in participants with Atopic Dermatitis.

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • ruxolitinib
  • Itch
  • Chronic Pruritus
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has clinically confirmed diagnosis of active AD for at least a 6-months.
  • Participant has chronic pruritus related to AD for at least 3 months .
  • Participant has an overall BSA (excluding palms, soles, scalp, genitals, and folds) affected by AD of 1%-20% on Day 1.
  • Participant has an IGA score of at least 2 on Day 1.
  • Participant has a single PP-NRS score ≥ 4 in the 24-hour period prior to the screening visit.
  • Willingness to avoid pregnancy or fathering children.
  • Participant must be willing to comply with all study procedures and restrictions including discontinuation of all current therapies for AD and pruritus (unless otherwise specified), and must be available for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Female participnat who is breastfeeding, pregnant, or planning to become pregnant during the study.

Participant had significant flares or unstable course in AD.

  • Participant has clinically infected AD or has used antibiotics (systemic or topical) for their infected AD within 2 weeks prior to the run-in period.
  • Participant has a history of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessments.
  • Participant has any medical condition or physical/laboratory/vital sign abnormality that would, in the opinion of the investigator, put the participant at undue risk or interfere with interpretation of study results.
  • Participant has received treatment with JAK inhibitors (systemic or topical) within 4 weeks prior to the run-in period.
  • Participant is unlikely, in the opinion of the investigator, to be compliant with study procedures and requirements.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Treatment Group : Ruxolitinib

    ruxolitinib cream 1.5% will be applied twice daily as a thin film.

    Drug: ruxolitinib cream

Interventions

  • ruxolitinib cream 1.5% will be applied twice daily as a thin film

    Also known as: INCB018424

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Day 2 (24-hour Recall Period After First Application)

    The intensity of pruritus (itch) was recorded daily using the PP-NRS (24-hour recall period). Participants were asked to assign a numerical score representing their itch at the worst moment during the previous 24 hours on a scale of 0 to 10, with 0 being no itch and 10 being the worst itch imaginable. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the average of all non-missing PP-NRS scores reported during the 7-day run-in period.

    Time frame: Baseline; Day 2

Secondary outcomes

  1. Change From Baseline in the Modified Peak-Pruritus Numerical Rating Scale (mPP-NRS) Score (Current Itch Intensity) at 15 and 30 Minutes Postdose and at 1, 2, 4, 6, and 12 Hours Postdose on Day 1

    On Day 1, participants were asked to evaluate the current intensity of their itch at the time of assessment (i.e., prior to the morning study drug application, and 15 and 30 minutes and 1, 2, 4, 6, and 12 hours after the morning study drug application; the 12-hour evaluation occurred prior to the second daily study drug application) on a scale from 0 to 10, with 0 indicating no itch and 10 indicating the worst imaginable itch. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the last non-missing assessment before or on Day 1 and prior to the first application of study drug (including unscheduled assessments).

    Time frame: Baseline; Day 1 (15 and 30 minutes postdose; 1, 2, 4, 6, and 12 hours postdose)

  2. Change From Baseline in the PP-NRS Score From Day 3 Through Day 29 (24-hour Recall Period After First Application)

    The intensity of pruritus (itch) was recorded daily using the PP-NRS (24-hour recall period). Participants were asked to assign a numerical score representing their itch at the worst moment during the previous 24 hours on a scale of 0 to 10, with 0 being no itch and 10 being the worst itch imaginable. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the average of all non-missing PP-NRS scores reported during the 7-day run-in period.

    Time frame: Baseline; Day 3 through Day 29

  3. Percentage of Participants Achieving at Least a 1-grade Decrease From Baseline in the mPP-NRS Score at 15 and 30 Minutes Postdose and at 1, 2, 4, 6, and 12 Hours Postdose on Day 1

    On Day 1, participants were asked to evaluate the current intensity of their itch at the time of assessment (i.e., prior to the morning study drug application, and 15 and 30 minutes and 1, 2, 4, 6, and 12 hours after the morning study drug application; the 12-hour evaluation occurred prior to the second daily study drug application) on a scale from 0 to 10, with 0 indicating no itch and 10 indicating the worst imaginable itch. Baseline was defined as the last non-missing assessment before or on Day 1 and prior to the first application of study drug (including unscheduled assessments). Confidence intervals were calculated using the Clopper-Pearson method.

    Time frame: Baseline; Day 1 (15 and 30 minutes postdose; 1, 2, 4, 6, and 12 hours postdose)

  4. Percentage of Participants Achieving at Least a 1-grade Decrease From Baseline in the PP-NRS Score From Day 2 Through Day 29

    The intensity of pruritus (itch) was recorded daily using the PP-NRS (24-hour recall period). Participants were asked to assign a numerical score representing their itch at the worst moment during the previous 24 hours on a scale of 0 to 10, with 0 being no itch and 10 being the worst itch imaginable. Baseline was defined as the average of all non-missing PP-NRS scores reported during the 7-day run-in period.

    Time frame: Baseline; Day 2 through Day 29

  5. Percentage of Participants Achieving at Least a 2-grade Decrease From Baseline in the mPP-NRS Score at 15 and 30 Minutes Postdose and at 1, 2, 4, 6, and 12 Hours Postdose on Day 1

    On Day 1, participants were asked to evaluate the current intensity of their itch at the time of assessment (i.e., prior to the morning study drug application, and 15 and 30 minutes and 1, 2, 4, 6, and 12 hours after the morning study drug application; the 12-hour evaluation occurred prior to the second daily study drug application) on a scale from 0 to 10, with 0 indicating no itch and 10 indicating the worst imaginable itch. Baseline was defined as the last non-missing assessment before or on Day 1 and prior to the first application of study drug (including unscheduled assessments).

    Time frame: Baseline; Day 1 (15 and 30 minutes postdose; 1, 2, 4, 6, and 12 hours postdose)

  6. Percentage of Participants Achieving at Least a 2-grade Decrease From Baseline in the PP-NRS Score From Day 2 Through Day 29

    The intensity of pruritus (itch) was recorded daily using the PP-NRS (24-hour recall period). Participants were asked to assign a numerical score representing their itch at the worst moment during the previous 24 hours on a scale of 0 to 10, with 0 being no itch and 10 being the worst itch imaginable. Baseline was defined as the average of all non-missing PP-NRS scores reported during the 7-day run-in period.

    Time frame: Baseline; Day 2 through Day 29

  7. Time to Minimal Clinically Important Difference (MCID) for PP-NRS (≥2-grade Reduction in PP-NRS From Baseline )

    The MCID corresponds to an achievement of a ≥2-grade reduction in PP-NRS from Baseline. The time to MCID was defined as the time from the date (time) of the first dose to the date (time) of the first occurrence of MCID. Baseline was defined as the average of all non-missing PP-NRS scores reported during the 7-day run-in period.

    Time frame: from Baseline up to Day 29

  8. Time to MCID for mPP-NRS (≥2-grade Reduction in mPP-NRS From Baseline)

    The MCID corresponds to an achievement of a ≥2-grade reduction in mPP-NRS from Baseline. The time to MCID was defined as the time from the date (time) of the first dose to the date (time) of the first occurrence of MCID. Baseline was defined as the last non-missing assessment before or on Day 1 and prior to the first application of study drug (including unscheduled assessments).

    Time frame: Baseline; Day 1

  9. Change From Baseline in Investigator Global Assessment (IGA) at Day 8, Day 15, and Day 29

    The IGA of the current state of the disease is a 5-point morphological assessment of overall disease severity. 0, clear: no erythema or induration/papulation, no oozing/crusting; there may be minor residual discoloration. 1, almost clear: there may be trace faint pink erythema with almost no induration/papulation and no oozing/crusting. 2, mild: there may be faint pink erythema with mild induration/papulation and no oozing/crusting. 3, moderate: there may be pink-red erythema with moderate induration/papulation, and there may be some oozing/crusting. 4, severe: there may be deep or bright red erythema with severe induration/papulation and with oozing/crusting.

    Time frame: Baseline; Days 8, 15, and 29

  10. Percentage of Participants Achieving Investigator Global Assessment-Treatment Success (IGA-TS) (Score of 0 or 1 in IGA With a ≥2-grade Reduction From Baseline) at Day 8, Day 15, and Day 29

    The IGA-TS is defined as an IGA score of 0 or 1 with a ≥2-grade reduction from Baseline. The IGA of the current state of the disease is a 5-point morphological assessment of overall disease severity. 0, clear: no erythema or induration/papulation, no oozing/crusting; there may be minor residual discoloration. 1, almost clear: there may be trace faint pink erythema with almost no induration/papulation and no oozing/crusting. 2, mild: there may be faint pink erythema with mild induration/papulation and no oozing/crusting. 3, moderate: there may be pink-red erythema with moderate induration/papulation, and there may be some oozing/crusting. 4, severe: there may be deep or bright red erythema with severe induration/papulation and with oozing/crusting.

    Time frame: Baseline; Days 8, 15, and 29

  11. Number of Participants With Any Treatment-emergent Adverse Event (TEAE)

    An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. TEAEs were defined as any AEs with an onset date during or after the first study treatment dose.

    Time frame: up to Day 43

  12. Number of Participants With Any Grade 3 or Higher TEAE

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. TEAEs were defined as any AEs with an onset date during or after the first study treatment dose. The severity of AEs were assessed using Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

    Time frame: up to Day 43

07

Results

Posted Oct 31, 2023

Participant flow

This study was conducted at 1 study center in Canada.

Participant flow — Overall Study
MilestoneRuxolitinib 1.5% Cream BID
Started49
Intent-to-treat population46
Completed44
Not completed5
Withdrew: Withdrawal by subject2
Withdrew: Dosed, but did not complete run-in period3

Outcome measures

PrimaryChange From Baseline in the Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Day 2 (24-hour Recall Period After First Application)

The intensity of pruritus (itch) was recorded daily using the PP-NRS (24-hour recall period). Participants were asked to assign a numerical score representing their itch at the worst moment during the previous 24 hours on a scale of 0 to 10, with 0 being no itch and 10 being the worst itch imaginable. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the average of all non-missing PP-NRS scores reported during the 7-day run-in period.

Time frame:
Baseline; Day 2
Reported as:
Mean · scores on a scale
Change From Baseline in the Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Day 2 (24-hour Recall Period After First Application)
scores on a scaleRuxolitinib 1.5% Cream BID
Baseline6.72 ± 1.363
Change from Baseline at Day 2-3.37 ± 1.847
SecondaryChange From Baseline in the Modified Peak-Pruritus Numerical Rating Scale (mPP-NRS) Score (Current Itch Intensity) at 15 and 30 Minutes Postdose and at 1, 2, 4, 6, and 12 Hours Postdose on Day 1

On Day 1, participants were asked to evaluate the current intensity of their itch at the time of assessment (i.e., prior to the morning study drug application, and 15 and 30 minutes and 1, 2, 4, 6, and 12 hours after the morning study drug application; the 12-hour evaluation occurred prior to the second daily study drug application) on a scale from 0 to 10, with 0 indicating no itch and 10 indicating the worst imaginable itch. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the last non-missing assessment before or on Day 1 and prior to the first application of study drug (including unscheduled assessments).

Time frame:
Baseline; Day 1 (15 and 30 minutes postdose; 1, 2, 4, 6, and 12 hours postdose)
Reported as:
Mean · scores on a scale
Change From Baseline in the Modified Peak-Pruritus Numerical Rating Scale (mPP-NRS) Score (Current Itch Intensity) at 15 and 30 Minutes Postdose and at 1, 2, 4, 6, and 12 Hours Postdose on Day 1
scores on a scaleRuxolitinib 1.5% Cream BID
Baseline6.4 ± 1.72
Change from Baseline at 15 minutes postdose-2.3 ± 2.34
Change from Baseline at 30 minutes postdose-3.0 ± 2.38
Change from Baseline at 1 hour postdose-3.3 ± 2.45
Change from Baseline at 2 hours postdose-3.8 ± 2.16
Change from Baseline at 4 hours postdose-4.2 ± 2.12
Change from Baseline at 6 hours postdose-4.2 ± 2.04
Change from Baseline at 12 hours postdose-3.1 ± 2.00
SecondaryChange From Baseline in the PP-NRS Score From Day 3 Through Day 29 (24-hour Recall Period After First Application)

The intensity of pruritus (itch) was recorded daily using the PP-NRS (24-hour recall period). Participants were asked to assign a numerical score representing their itch at the worst moment during the previous 24 hours on a scale of 0 to 10, with 0 being no itch and 10 being the worst itch imaginable. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the average of all non-missing PP-NRS scores reported during the 7-day run-in period.

Time frame:
Baseline; Day 3 through Day 29
Reported as:
Mean · scores on a scale
Change From Baseline in the PP-NRS Score From Day 3 Through Day 29 (24-hour Recall Period After First Application)
scores on a scaleRuxolitinib 1.5% Cream BID
Baseline6.72 ± 1.363
Change from Baseline at Day 3-3.78 ± 1.775
Change from Baseline at Day 4-4.00 ± 1.760
Change from Baseline at Day 5-4.20 ± 1.875
Change from Baseline at Day 6-4.58 ± 1.935
Change from Baseline at Day 7-4.78 ± 1.755
Change from Baseline at Day 8-4.91 ± 1.832
Change from Baseline at Day 9-4.92 ± 1.890
Change from Baseline at Day 10-5.00 ± 1.762
Change from Baseline at Day 11-5.19 ± 1.606
Change from Baseline at Day 12-5.19 ± 1.722
Change from Baseline at Day 13-5.03 ± 1.907
Change from Baseline at Day 14-5.10 ± 1.745
Change from Baseline at Day 15-5.03 ± 1.805
Change from Baseline at Day 16-5.30 ± 1.680
Change from Baseline at Day 17-5.28 ± 1.510
Change from Baseline at Day 18-5.34 ± 1.826
Change from Baseline at Day 19-5.37 ± 1.739
Change from Baseline at Day 20-5.40 ± 1.759
Change from Baseline at Day 21-5.52 ± 1.692
Change from Baseline at Day 22-5.56 ± 1.726
Change from Baseline at Day 23-5.50 ± 1.598
Change from Baseline at Day 24-5.28 ± 1.773
Change from Baseline at Day 25-5.65 ± 1.629
Change from Baseline at Day 26-5.68 ± 1.585
Change from Baseline at Day 27-5.69 ± 1.689
Change from Baseline at Day 28-5.39 ± 1.845
Change from Baseline at Day 29-5.68 ± 1.595
SecondaryPercentage of Participants Achieving at Least a 1-grade Decrease From Baseline in the mPP-NRS Score at 15 and 30 Minutes Postdose and at 1, 2, 4, 6, and 12 Hours Postdose on Day 1

On Day 1, participants were asked to evaluate the current intensity of their itch at the time of assessment (i.e., prior to the morning study drug application, and 15 and 30 minutes and 1, 2, 4, 6, and 12 hours after the morning study drug application; the 12-hour evaluation occurred prior to the second daily study drug application) on a scale from 0 to 10, with 0 indicating no itch and 10 indicating the worst imaginable itch. Baseline was defined as the last non-missing assessment before or on Day 1 and prior to the first application of study drug (including unscheduled assessments). Confidence intervals were calculated using the Clopper-Pearson method.

Time frame:
Baseline; Day 1 (15 and 30 minutes postdose; 1, 2, 4, 6, and 12 hours postdose)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving at Least a 1-grade Decrease From Baseline in the mPP-NRS Score at 15 and 30 Minutes Postdose and at 1, 2, 4, 6, and 12 Hours Postdose on Day 1
percentage of participantsRuxolitinib 1.5% Cream BID
15 minutes postdose82.6 (68.6 to 92.2)
30 minutes postdose89.1 (76.4 to 96.4)
1 hour postdose89.1 (76.4 to 96.4)
2 hours postdose97.8 (88.5 to 99.9)
4 hours postdose100.0 (92.3 to 100.0)
6 hours postdose97.8 (88.5 to 99.9)
12 hours postdose90.7 (77.9 to 97.4)
SecondaryPercentage of Participants Achieving at Least a 1-grade Decrease From Baseline in the PP-NRS Score From Day 2 Through Day 29

The intensity of pruritus (itch) was recorded daily using the PP-NRS (24-hour recall period). Participants were asked to assign a numerical score representing their itch at the worst moment during the previous 24 hours on a scale of 0 to 10, with 0 being no itch and 10 being the worst itch imaginable. Baseline was defined as the average of all non-missing PP-NRS scores reported during the 7-day run-in period.

Time frame:
Baseline; Day 2 through Day 29
Reported as:
Number · percentage of participants
Percentage of Participants Achieving at Least a 1-grade Decrease From Baseline in the PP-NRS Score From Day 2 Through Day 29
percentage of participantsRuxolitinib 1.5% Cream BID
Day 293.3 (81.7 to 98.6)
Day 395.6 (84.9 to 99.5)
Day 497.8 (88.2 to 99.9)
Day 597.8 (88.5 to 99.9)
Day 697.8 (88.2 to 99.9)
Day 797.8 (88.5 to 99.9)
Day 897.8 (88.2 to 99.9)
Day 997.8 (88.2 to 99.9)
Day 1097.7 (88.0 to 99.9)
Day 11100.0 (92.1 to 100.0)
Day 12100.0 (92.1 to 100.0)
Day 13100.0 (92.1 to 100.0)
Day 1497.8 (88.2 to 99.9)
Day 15100.0 (92.1 to 100.0)
Day 16100.0 (92.1 to 100.0)
Day 17100.0 (92.1 to 100.0)
Day 18100.0 (92.1 to 100.0)
Day 1997.8 (88.2 to 99.9)
Day 2097.7 (87.7 to 99.9)
Day 21100.0 (92.1 to 100.0)
Day 22100.0 (92.0 to 100.0)
Day 23100.0 (92.1 to 100.0)
Day 2497.8 (88.2 to 99.9)
Day 25100.0 (92.1 to 100.0)
Day 26100.0 (92.1 to 100.0)
Day 27100.0 (92.0 to 100.0)
Day 2897.7 (88.0 to 99.9)
Day 29100.0 (91.6 to 100.0)
SecondaryPercentage of Participants Achieving at Least a 2-grade Decrease From Baseline in the mPP-NRS Score at 15 and 30 Minutes Postdose and at 1, 2, 4, 6, and 12 Hours Postdose on Day 1

On Day 1, participants were asked to evaluate the current intensity of their itch at the time of assessment (i.e., prior to the morning study drug application, and 15 and 30 minutes and 1, 2, 4, 6, and 12 hours after the morning study drug application; the 12-hour evaluation occurred prior to the second daily study drug application) on a scale from 0 to 10, with 0 indicating no itch and 10 indicating the worst imaginable itch. Baseline was defined as the last non-missing assessment before or on Day 1 and prior to the first application of study drug (including unscheduled assessments).

Time frame:
Baseline; Day 1 (15 and 30 minutes postdose; 1, 2, 4, 6, and 12 hours postdose)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving at Least a 2-grade Decrease From Baseline in the mPP-NRS Score at 15 and 30 Minutes Postdose and at 1, 2, 4, 6, and 12 Hours Postdose on Day 1
percentage of participantsRuxolitinib 1.5% Cream BID
15 minutes postdose58.7 (43.2 to 73.0)
30 minutes postdose67.4 (52.0 to 80.5)
1 hour postdose71.7 (56.5 to 84.0)
2 hours postdose91.3 (79.2 to 97.6)
4 hours postdose95.7 (85.2 to 99.5)
6 hours postdose93.5 (82.1 to 98.6)
12 hours postdose76.7 (61.4 to 88.2)
SecondaryPercentage of Participants Achieving at Least a 2-grade Decrease From Baseline in the PP-NRS Score From Day 2 Through Day 29

The intensity of pruritus (itch) was recorded daily using the PP-NRS (24-hour recall period). Participants were asked to assign a numerical score representing their itch at the worst moment during the previous 24 hours on a scale of 0 to 10, with 0 being no itch and 10 being the worst itch imaginable. Baseline was defined as the average of all non-missing PP-NRS scores reported during the 7-day run-in period.

Time frame:
Baseline; Day 2 through Day 29
Reported as:
Number · percentage of participants
Percentage of Participants Achieving at Least a 2-grade Decrease From Baseline in the PP-NRS Score From Day 2 Through Day 29
percentage of participantsRuxolitinib 1.5% Cream BID
Day 271.1 (55.7 to 83.6)
Day 382.2 (67.9 to 92.0)
Day 484.4 (70.5 to 93.5)
Day 587.0 (73.7 to 95.1)
Day 691.1 (78.8 to 97.5)
Day 795.7 (85.2 to 99.5)
Day 893.3 (81.7 to 98.6)
Day 995.6 (84.9 to 99.5)
Day 1095.5 (84.5 to 99.4)
Day 1197.8 (88.2 to 99.9)
Day 1297.8 (88.2 to 99.9)
Day 1395.6 (84.9 to 99.5)
Day 1497.8 (88.2 to 99.9)
Day 1597.8 (88.2 to 99.9)
Day 16100.0 (92.1 to 100.0)
Day 1797.8 (88.2 to 99.9)
Day 1895.6 (84.9 to 99.5)
Day 1995.6 (84.9 to 99.5)
Day 2097.7 (87.7 to 99.9)
Day 2197.8 (88.2 to 99.9)
Day 2297.7 (88.0 to 99.9)
Day 23100.0 (92.1 to 100.0)
Day 2495.6 (84.9 to 99.5)
Day 25100.0 (92.1 to 100.0)
Day 26100.0 (92.1 to 100.0)
Day 2797.7 (88.0 to 99.9)
Day 2895.5 (84.5 to 99.4)
Day 2997.6 (87.4 to 99.9)
SecondaryTime to Minimal Clinically Important Difference (MCID) for PP-NRS (≥2-grade Reduction in PP-NRS From Baseline )

The MCID corresponds to an achievement of a ≥2-grade reduction in PP-NRS from Baseline. The time to MCID was defined as the time from the date (time) of the first dose to the date (time) of the first occurrence of MCID. Baseline was defined as the average of all non-missing PP-NRS scores reported during the 7-day run-in period.

Time frame:
from Baseline up to Day 29
Reported as:
Mean · days
Time to Minimal Clinically Important Difference (MCID) for PP-NRS (≥2-grade Reduction in PP-NRS From Baseline )
daysRuxolitinib 1.5% Cream BID
Time to Minimal Clinically Important Difference (MCID) for PP-NRS (≥2-grade Reduction in PP-NRS From Baseline )1.6 ± 1.42
SecondaryTime to MCID for mPP-NRS (≥2-grade Reduction in mPP-NRS From Baseline)

The MCID corresponds to an achievement of a ≥2-grade reduction in mPP-NRS from Baseline. The time to MCID was defined as the time from the date (time) of the first dose to the date (time) of the first occurrence of MCID. Baseline was defined as the last non-missing assessment before or on Day 1 and prior to the first application of study drug (including unscheduled assessments).

Time frame:
Baseline; Day 1
Reported as:
Mean · hours
Time to MCID for mPP-NRS (≥2-grade Reduction in mPP-NRS From Baseline)
hoursRuxolitinib 1.5% Cream BID
Time to MCID for mPP-NRS (≥2-grade Reduction in mPP-NRS From Baseline)0.817 ± 0.9788
SecondaryChange From Baseline in Investigator Global Assessment (IGA) at Day 8, Day 15, and Day 29

The IGA of the current state of the disease is a 5-point morphological assessment of overall disease severity. 0, clear: no erythema or induration/papulation, no oozing/crusting; there may be minor residual discoloration. 1, almost clear: there may be trace faint pink erythema with almost no induration/papulation and no oozing/crusting. 2, mild: there may be faint pink erythema with mild induration/papulation and no oozing/crusting. 3, moderate: there may be pink-red erythema with moderate induration/papulation, and there may be some oozing/crusting. 4, severe: there may be deep or bright red erythema with severe induration/papulation and with oozing/crusting.

Time frame:
Baseline; Days 8, 15, and 29
Reported as:
Mean · scores on a scale
Change From Baseline in Investigator Global Assessment (IGA) at Day 8, Day 15, and Day 29
scores on a scaleRuxolitinib 1.5% Cream BID
Baseline2.9 ± 0.31
Change from Baseline a Day 8-1.4 ± 0.73
Change from Baseline at Day 15-2.0 ± 0.87
Change from Baseline at Day 29-2.2 ± 0.90
SecondaryPercentage of Participants Achieving Investigator Global Assessment-Treatment Success (IGA-TS) (Score of 0 or 1 in IGA With a ≥2-grade Reduction From Baseline) at Day 8, Day 15, and Day 29

The IGA-TS is defined as an IGA score of 0 or 1 with a ≥2-grade reduction from Baseline. The IGA of the current state of the disease is a 5-point morphological assessment of overall disease severity. 0, clear: no erythema or induration/papulation, no oozing/crusting; there may be minor residual discoloration. 1, almost clear: there may be trace faint pink erythema with almost no induration/papulation and no oozing/crusting. 2, mild: there may be faint pink erythema with mild induration/papulation and no oozing/crusting. 3, moderate: there may be pink-red erythema with moderate induration/papulation, and there may be some oozing/crusting. 4, severe: there may be deep or bright red erythema with severe induration/papulation and with oozing/crusting.

Time frame:
Baseline; Days 8, 15, and 29
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Investigator Global Assessment-Treatment Success (IGA-TS) (Score of 0 or 1 in IGA With a ≥2-grade Reduction From Baseline) at Day 8, Day 15, and Day 29
percentage of participantsRuxolitinib 1.5% Cream BID
Day 845.5 (30.4 to 61.2)
Day 1571.1 (55.7 to 83.6)
Day 2977.3 (62.2 to 88.5)
SecondaryNumber of Participants With Any Treatment-emergent Adverse Event (TEAE)

An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. TEAEs were defined as any AEs with an onset date during or after the first study treatment dose.

Time frame:
up to Day 43
Reported as:
Number · participants
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
participantsRuxolitinib 1.5% Cream BID
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)15
SecondaryNumber of Participants With Any Grade 3 or Higher TEAE

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. TEAEs were defined as any AEs with an onset date during or after the first study treatment dose. The severity of AEs were assessed using Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

Time frame:
up to Day 43
Reported as:
Number · participants
Number of Participants With Any Grade 3 or Higher TEAE
participantsRuxolitinib 1.5% Cream BID
Number of Participants With Any Grade 3 or Higher TEAE0

Adverse events

Collected over up to Day 43. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ruxolitinib 1.5% Cream BID0/49 (0%)0/49 (0%)15/49 (30.6%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventRuxolitinib 1.5% Cream BID
COVID-19Infections and infestations3/49
Back painMusculoskeletal and connective tissue disorders2/49
HeadacheNervous system disorders2/49
NasopharyngitisInfections and infestations2/49
Upper respiratory tract infectionInfections and infestations2/49
AcneSkin and subcutaneous tissue disorders1/49
ConcussionInjury, poisoning and procedural complications1/49
EpistaxisRespiratory, thoracic and mediastinal disorders1/49
Eye pruritusEye disorders1/49
GastroenteritisInfections and infestations1/49

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ruxolitinib 1.5% Cream BID
Mean35.6 ± 14.77
Sex: Female, Male
Sex: Female, Male(Participants)Ruxolitinib 1.5% Cream BID
Female35
Male14
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ruxolitinib 1.5% Cream BID
Hispanic or Latino4
Not Hispanic or Latino45
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ruxolitinib 1.5% Cream BID
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American5
White42
More than one race0
Unknown or Not Reported0
08

Study locations

2 sites
  • Innovaderm Research Inc.
    Montreal, Quebec H2K 4L5, Canada
  • Innovoderm Research
    Montreal, Quebec H2K 4LS, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Nov 2022, 13 months.

Results were first posted in Oct 2023, 11 months after primary completion.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 13 months is close to that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2021
First posted
Apr 9, 2021
StartActual
Oct 12, 2021
Primary completionActual
Nov 18, 2022
CompletionActual
Nov 18, 2022
Results first posted
Oct 31, 2023
Last update
Oct 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04839380
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Apr 9, 2021
Start date
Oct 12, 2021
Primary completion
Nov 18, 2022
Completion
Nov 18, 2022
Results posted
Oct 31, 2023
Last update
Oct 31, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion